Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04394754
Other study ID # 2000027325
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 21, 2020
Est. completion date December 1, 2021

Study information

Verified date April 2023
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy of three novel digital health technologies versus usual care in the management of congestive heart failure, as assessed by a primary outcome of improvement in quality of life, and a variety of secondary outcomes that include metrics measuring patient and provider satisfaction, clinical efficiency, and patient outcomes.


Description:

Heart failure is the most common cause of mortality and morbidity in the United States and in Western Europe. However, patient etiology and prognosis varies considerably, and guidance about how to best treat patients has relied on large clinical trials that only include snapshots of the syndrome (at the time the patient interaction with the healthcare system). It remains to be seen whether behavioral interventions can improve patient engagement, increase self-management of the conditions, and thus improve overall clinical outcomes. Digital health technologies have a great potential to streamline and optimize the clinical management of heart failure. Such technologies can take the form of mobile applications or wearable devices that may provide both patients and providers with valuable real-time information about patient status and cardiovascular health, provide automated patient-tailored coaching and motivational tools, or a mix of both. Integration of these technologies into healthcare systems may allow for genuine engagement of the patient in their own care and management of their disease and/or enhance clinical decision making. To date, no prior study has comprehensively examined the ability of digital heath technologies to improve self-management of heart failure or subsequent clinical outcomes. This study is an unblinded, 4-arm, parallel group randomized controlled trial to measure the efficacy of four digital health technologies in improving the management of care and quality of life of patients with congestive heart failure (CHF). Patients actively managed by one of Yale New Haven Hospital's heart failure-based clinics will be eligible for this study and approached for consent. Enrolled subjects will be randomized to one of four groups: a control (usual care) arm, or to one of three intervention arms, each of which assesses one of three digital health technologies. These technologies are: - BodyPort: A data-driven smart scale that provides enhanced cardiac monitoring and risk assessment data. - Noom: A live, data-driven coaching application providing personalized diet and weight management. - Conversa: An automated conversational platform providing patient motivation and educational tools for CHF management. Patients will be enrolled in the study for 6 months. The first three months will typically involve active clinic management and will be the point of our primary outcome assessment, while the final three months will assess stability of effect on patient care and outcomes. The primary outcome is the rate of improvement in quality of life after 90 days post-enrollment, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). A variety of prespecified secondary outcomes will be measured to determine effects on patient outcomes, quality of care, clinical efficiency, and provider and patient satisfaction with the product.


Recruitment information / eligibility

Status Completed
Enrollment 182
Est. completion date December 1, 2021
Est. primary completion date September 20, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: - Adults greater than or equal to 18 and less than 80 years of age - Enrolled in one of Yale New Haven Hospital's Disease Management or Heart Failure-focused cardiology clinics - Diagnosed with congestive heart failure (preserved or reduced ejection fraction with or without diabetes) Exclusion Criteria: - Class IV heart failure - Stage 4 or end stage renal disease (eGFR < 30) - Recipient of a heart transplant of ventricular assist device - Under hospice care - Dementia - Incarceration - Pregnancy - Currently homeless or residing in an unstable living situation (i.e., transitional housing, rehab facility, etc.) - Inability to consent - Currently enrolled in a study investigating a digital health product or technology - Life expectancy of less than 6 months as determined by clinical judgement of primary treating physician - weight greater than 400 pounds - unable to stand straight up for 30 seconds without assistance, such as from a cane, walker, or wall. - non-English speaking

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BodyPort
Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.
Other:
Noom
Patients will receive a subscription to use Noom, a personalized diet and weight management application.
Conversa
patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.

Locations

Country Name City State
United States Yale New Haven Hospital New Haven Connecticut

Sponsors (3)

Lead Sponsor Collaborator
Yale University Boehringer Ingelheim, Medullan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Quality of Life at 90 Days Post Enrollment Assessed by the change in score of the Kansas City Cardiomyopathy Questionnaire (KCCQ) survey between baseline scoring (at enrollment) and at 90 days post-enrollment. This survey is a 23 item self-administered instrument used to quantify a patient's perception of health status. For each domain reported, an overall summary scored is derived and transformed to a score range of 0-100. The Total Symptom score is the mean of the Symptom Frequency and Symptom Burden scores. The Overall Summary Score is the mean of the Physical Limitation, Total Symptom, Quality of Life and Social Limitation Scores. The Clinical Summary score is the mean of the Physical Limitation and Total Symptom scores. All KCCQ scores are summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent. Day 90 after enrollment
Secondary Change in Quality of Life at 180 Days Post Enrollment Assessed by the change in score of the Kansas City Cardiomyopathy Questionnaire (KCCQ) survey between day 90 post enrollment and at day 180 post enrollment. This survey is a 23 item self-administered instrument used to quantify a patient's perception of health status. For each domain reported, an overall summary scored is derived and transformed to a score range of 0-100. The Total Symptom score is the mean of the Symptom Frequency and Symptom Burden scores. The Overall Summary Score is the mean of the Physical Limitation, Total Symptom, Quality of Life and Social Limitation Scores. The Clinical Summary score is the mean of the Physical Limitation and Total Symptom scores. All KCCQ scores are summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent. 180 days post enrollment
Secondary Number of Participants With Hospital Admission at 90 Days Post Enrollment Via medical record review. Number of patients with a hospital admission between enrollment to day 90 post enrollment. 90 days post enrollment
Secondary Number of Participants With Hospital Admission at 180 Days Post Enrollment Via medical record review. This measure is calculated as the number of participants with a hospital admission from day 90 to day 180 post enrollment. 180 days post enrollment
Secondary Prescribing of Guideline-directed Medical Therapy Documented prescription or change in dosing of any one of the following medication classes: beta blockers, ACEi/ARBs, and/or spironolactone; assessed via Surescripts data collection. 90 days post enrollment
Secondary Prescribing of Guideline-directed Medical Therapy Documented prescription or change in dosing of any one of the following medication classes: beta blockers, ACEi/ARBs, and/or spironolactone; assessed via Surescripts data collection. 180 days post enrollment
Secondary Number of Subjects Using Guideline-directed Medical Therapy at 90 Days Post Enrollment Number of patients having documented prescription of all of the following medication classes between enrollment and day 90 post enrollment: beta blockers, angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNI), sodium/glucose cotransporter-2 inhibitors (SGLT2i) and aldosterone receptor antagonists (MRAs); assessed via Surescripts data collection. 90 days post enrollment
Secondary Number of Subjects Using Guideline-directed Medical Therapy at 180 Days Post Enrollment Number of patients having documented prescription of all of the following medication classes between day 90 post enrollment and day 180 post enrollment: beta blockers, angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARBs)/angiotensin receptor-neprilysin inhibitors (ARNI), sodium/glucose cotransporter-2 inhibitors (SGLT2i) and aldosterone receptor antagonists (MRAs); assessed via Surescripts data collection. 180 days post enrollment
Secondary Number of Participants With Emergency Department (ED) Visits at 90 Days Post Enrollment Via medical record review. Number of participants with an emergency department visit between enrollment and day 90 post enrollment. 90 days post enrollment
Secondary Number of Participants With Emergency Department Visits at 180 Days Post Enrollment Via medical record review. Number of participants with an emergency department visit between day 90 and day 180 post enrollment. 180 days post enrollment
Secondary Number of Participants With Acute Kidney Injury (AKI) Development at 90 Days Post Enrollment Via medical record review, defined as an increase in serum creatinine by 50% over baseline (pre-enrollment creatinine) at any point between enrollment day 90 post enrollment. 90 days post enrollment
Secondary Number of Participants With Acute Kidney Injury (AKI) Development at 180 Days Post Enrollment Via medical record review, defined as an increase in serum creatinine by 50% over baseline (pre-enrollment creatinine) at any point between day 90 and day 180 post enrollment. 180 days post enrollment
Secondary Mortality Rate at 90 Days Post Enrollment Via medical record review. Number of deaths between enrollment and 90 days post enrollment. 90 days post enrollment
Secondary Mortality Rates at 180 Days Post Enrollment Via medical record review. Number of deaths between day 90 and day 180 post enrollment. 180 days post enrollment
Secondary Number of Participants With at Least One Clinic No-show at 90 Days Post Enrollment Via medical record review; number of participants with at least one clinic no show between enrollment and day 90 post enrollment. 90 days post enrollment
Secondary Number of In-person and Remote Clinic Visits at 90 Days Post Enrollment Via medical record review. Number of visits between enrollment and 90 days post enrollment. 90 days post enrollment
Secondary Number of In-person and Remote Clinic Visits at 180 Days Post Enrollment Via medical record review. Number of visits between day 90 and day 180 post enrollment. 180 days post enrollment
Secondary Number of Remote Device Checks by Providers at 90 Days Post Enrollment Via medical record review 90 days post enrollment
Secondary Number of Remote Device Checks by Providers at 180 Days Post Enrollment Via medical record review 180 days post enrollment
Secondary Number of Phone Calls Between Provider and Participant at 90 Days Post Enrollment Via medical record review of telephone logs between enrollment and day 90 post enrollment. 90 days post enrollment
Secondary Number of Phone Calls Between Provider and Participant at 180 Days Post Enrollment Via medical record review of telephone logs 180 days post enrollment
Secondary Average Time Devoted by Provider to Patient Care Via medical record review of chart openings per patient 90 days post enrollment
Secondary Average Time Devoted by Provider to Patient Care Via medical record review of chart openings per patient 180 days post enrollment
Secondary Number of Subjects Who Complete on Boarding and Baseline Assessments Collected from patient enrollment platform Within one week of consent
Secondary Number of Subjects Who Complete Digital Health Product Set up Assessed as number of subjects who used device at least once during their duration in the study, up to 90 days post enrollment. 90 days post enrollment
Secondary Number of Weekly Interactions With the Device Information collected from device metrics to assess frequency of use 90 days post enrollment
Secondary Number of Weekly Interactions With the Device Information collected from device metrics to assess frequency of use 180 days post enrollment
Secondary Average Number of Daily Interactions With the Device Information collected from device metric to assess frequency of use 90 days post enrollment
Secondary Average Number of Daily Interactions With the Device Information collected from device metric to assess frequency of use 180 days post enrollment
See also
  Status Clinical Trial Phase
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT04037436 - Functional Exercise and Nutrition Education Program for Older Adults N/A
Recruiting NCT04703842 - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction Phase 1/Phase 2
Terminated NCT05594940 - Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility Study
Recruiting NCT04982081 - Treating Congestive HF With hiPSC-CMs Through Endocardial Injection Phase 1
Active, not recruiting NCT01385176 - Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) N/A
Not yet recruiting NCT05516290 - Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
Terminated NCT02788656 - Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan) Phase 4
Completed NCT02885636 - Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial Phase 3
Terminated NCT02205411 - Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation N/A
Completed NCT02252757 - Assess Measurements of Wireless Cardiac Output Device N/A
Completed NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Withdrawn NCT00346177 - Stem Cell Study for Patients With Heart Failure Phase 2
Active, not recruiting NCT01058837 - SCD-HeFT 10 Year Follow-up N/A
Completed NCT00957541 - Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device Phase 2
Recruiting NCT01099982 - Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease